From the press release:
This exciting SCLC meeting features Amgen's Vice President, US Head of Oncology Medical Affairs, Byeong Yoon, PhD will provide an in-depth look at their recently FDA approved treatment option for ES (Extensive Stage)-SCLC, IMDELLTRA (Tarlatamab).
Because this is a new treatment option for ES-SCLC, and this is an incredible opportunity for SCLC patients and their care partners to learn more about and ask questions about this treatment, we would love to get this information out to as many people as possible.
What: LiveLung virtual SCLC meeting
When: Monday, September 30 at 7 pm ET.
Speaker: Vice President, Head of Amgen’s US Oncology Medical Affairs team, Byeong Yoon, PhD. Dr. Yoon
Topic: An in-depth look at the recently FDA approved IMDELLTRA (Tarlatamab).
Why Important: This is an excellent opportunity to learn more about this new treatment option for ES-SCLC and to ask questions about it.
Registration Link: us02web.zoom.us/meeting/reg...
